MedTrace Logo

12-hour Versus 24-hour Postpartum Magnesium Sulphate for Preeclamptic Patients

NCT04576364 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 280

Last updated 2023-09-01

No results posted yet for this study

Summary

To compare the use of magnesium sulfate for 12 hours versus 24 hours in postpartum women with pre-eclampsia with severe features , to ensure maximum efficacy of anticonvulsant action that can be achieved with least exposure to Mgso4 side effects.

Conditions

  • Maternal Care Patterns

Interventions

DRUG

Magnesium sulfate for 12 hour

drug used to prevent convulsions in patients having preeclampsia with severe features

DRUG

Magnesium sulfate for 24 hour

drug used to prevent convulsions in patients having preeclampsia with severe features

Sponsors & Collaborators

  • Assiut University

    lead OTHER

Principal Investigators

  • ِAhmed Fayek, Proffessor · Assiut University

  • sherif Badran, Lecturer · Assiut University

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-01
Primary Completion
2022-11-20
Completion
2022-11-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04576364 on ClinicalTrials.gov